{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"SunRISe-3","nct_id":"NCT05714202","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sunrise-3-nct05714202. The price is quoted from the commentary indexed so far and fixed at order. Final coverage is set when the report is built. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SunRISe-3","arms":[{"description":"Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.","label":"Treatment Group A: TAR-200 + Cetrelimab","type":"EXPERIMENTAL"},{"description":"Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance).","label":"Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive intravesical TAR-200 alone once Q3W.","label":"Treatment Group C: TAR-200 Alone","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-09-18","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":1135,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"TAR-200","type":"DRUG"},{"name":"Cetrelimab","type":"BIOLOGICAL"},{"name":"BCG Vesiculture","type":"BIOLOGICAL"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-09-18","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free Survival (EFS)","timeFrame":"Up to 5 years 2 months"}],"references":[],"start_date":{"date":"2023-03-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","url":"https://clinicaltrials.gov/study/NCT05714202"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sunrise-3-nct05714202"}